Patents by Inventor Wouter Eilers

Wouter Eilers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11944688
    Abstract: The invention relates to improvements in drug delivery and more particularly to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to form Stapled CPP's (StaP's) or ii) stitching three or more amino acids to form stitched CPP's (StiP's). These stabilized CPP's are conjugated to a drug or Biologically Active Compound (BAC) directly or via a Bi-Functional Linker (BFL) so that the BAC can be carried though a cell membrane by the CPP. The resulting molecules are referred to as Drug Carrying Cell Penetrating Molecules (DCCPM's). The preferred BAC is an electrically low charge carrying oligonucleotide such as a phosphorodiamidate morpholino oligonucleotide (PMO).
    Type: Grant
    Filed: December 27, 2022
    Date of Patent: April 2, 2024
    Assignee: SUTURA THERAPEUTICS LTD
    Inventors: Keith Foster, Wouter Eilers, Adam James Reginald Gadd
  • Publication number: 20230158166
    Abstract: The invention relates to improvements in drug delivery and more particularly to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to form Stapled CPP's (StaP's) or ii) stitching three or more amino acids to form stitched CPP's (StiP's). These stabilized CPP's are conjugated to a drug or Biologically Active Compound (BAC) directly or via a Bi-Functional Linker (BFL) so that the BAC can be carried though a cell membrane by the CPP. The resulting molecules are referred to as Drug Carrying Cell Penetrating Molecules (DCCPM's). The preferred BAC is an electrically low charge carrying oligonucleotide such as a phosphorodiamidate morpholino oligonucleotide (PMO).
    Type: Application
    Filed: December 27, 2022
    Publication date: May 25, 2023
    Inventors: Keith Foster, Wouter Eilers, Adam James Reginald Gadd
  • Publication number: 20230082321
    Abstract: The present disclosure provides a method for preparing microbeads comprising nanofibrillar cellulose, the method comprising providing a dispersion of chemically anionically modified nanofibrillar cellulose having a number-average diameter of 200 nm or less, forming the nanofibrillar cellulose into microbeads, to obtain microbeads comprising chemically anionically modified nanofibrillar cellulose in the range of 0.2-2% by weight. The present disclosure also provides the microbeads, a cell culture, a method for providing cell-derived products, use of the microbeads and use of chemically anionically modified nanofibrillar cellulose for preparing the microbeads.
    Type: Application
    Filed: September 7, 2022
    Publication date: March 16, 2023
    Inventors: Markus NUOPPONEN, Jonathan SHEARD, Wouter EILERS, Darius WIDERA, Graeme S. COTTRELL, Karen COOPMAN, Lisa BARRETT, Marijana DRAGOSAVAC
  • Patent number: 11541124
    Abstract: The invention relates to improvements in drug delivery and more particularly to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to form Stapled CPP's (StaP's) or ii) stitching three or more amino acids to form stitched CPP's (StiP's). These stabilized CPP's are conjugated to a drug or Biologically Active Compound (BAC) directly or via a Bi-Functional Linker (BFL) so that the BAC can be carried through a cell membrane by the CPP. The resulting molecules are referred to as Drug Carrying Cell Penetrating Molecules (DCCPM's). The preferred BAC is an electrically low charge carrying oligonucleotide such as a phosphorodiamidate morpholino oligonucleotide (PMO).
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: January 3, 2023
    Assignee: SUTURA THERAPEUTICS LTD
    Inventors: Keith Foster, Wouter Eilers, Adam James Reginald Gadd
  • Publication number: 20200353092
    Abstract: The invention relates to improvements in drug delivery and more particularly to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to form Stapled CPP's (StaP's) or ii) stitching three or more amino acids to form stitched CPP's (StiP's). These stabilized CPP's are conjugated to a drug or Biologically Active Compound (BAC) directly or via a Bi-Functional Linker (BFL) so that the BAC can be carried though a cell membrane by the CPP. The resulting molecules are referred to as Drug Carrying Cell Penetrating Molecules (DCCPM's). The preferred BAC is an electrically low charge carrying oligonucleotide such as a phosphorodiamidate morpholino oligonucleotide (PMO).
    Type: Application
    Filed: December 21, 2016
    Publication date: November 12, 2020
    Applicant: Sutura Therapeutics Ltd
    Inventors: Keith Foster, Wouter Eilers, Adam James Reginald Gadd